Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NA17.A2 peptide vaccine

A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	NA17.A2

NA17.A2 peptide vaccine

Search NCI's Drug Dictionary